Patents by Inventor David J. Augeri

David J. Augeri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220227735
    Abstract: The invention provides a compound of formula I: (I) or a pharmaceutically acceptable salt thereof, wherein R1-R5 Y have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful to treat malaria.
    Type: Application
    Filed: April 22, 2020
    Publication date: July 21, 2022
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Purnima BHANOT, David J. AUGERI, John A. GILLERAN, Raheel FONDEKAR
  • Publication number: 20220002296
    Abstract: The invention provides compounds of formula (16) and (17); and salts thereof, as well as compositions comprising such compounds and salts, complexes comprising such compounds and salts, and methods for treating cancer, inhibiting BMI1 expression, or treating Huntington's disease using such compounds, salts, and complexes. The compounds, salts, and complexes have potency, permeability, and oral bioavailability that make them particularly useful, for example, for the treatment of glioblastoma.
    Type: Application
    Filed: November 26, 2019
    Publication date: January 6, 2022
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: David J. AUGERI, Hatem SABAAWY, John A. GILLERAN
  • Patent number: 10875861
    Abstract: The invention provides a compound of formula I: or a salt thereof, wherein R2-R4 and p have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as anti-cancer agents.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: December 29, 2020
    Assignee: Rutgers, the State University of New Jersey
    Inventors: David J. Augeri, Hatem E. Sabaawy
  • Patent number: 10828288
    Abstract: The invention provides compounds of formula (I): and salts thereof wherein ring A, R2, HET, X, n, and R3 have any of the meanings described in the specification, as well as compositions comprising such compounds and salts, and methods for treating cancer using such compounds and salts.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: November 10, 2020
    Assignees: Rutgers, the State University of New Jersey, The Research Foundation for the State University of New York
    Inventors: David J. Augeri, Anthony F. Bencivenga, Adam Blanden, Darren R. Carpizo, John A. Gilleran, Spencer David Kimball, Stewart N. Loh, Xin Yu
  • Patent number: 10729671
    Abstract: The invention provides complexes of Zn2+ of formulae (la) and (IIa) that are useful for treating cancer, as well as compositions and kits comprising such complexes.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: August 4, 2020
    Assignees: Rutgers, the State University of New Jersey, The Research Foundation for the State University of New York
    Inventors: David J. Augeri, Anthony F. Bencivenga, Adam Blanden, Darren R. Carpizo, John A. Gilleran, Spencer David Kimball, Stewart N. Loh, Xin Yu
  • Patent number: 10604481
    Abstract: The invention provides organic complexes of Zn2+ that are useful for treating cancer, as well as compositions and kits comprising such complexes, and intermediate monomer compounds that are useful for the preparation of such complexes.
    Type: Grant
    Filed: January 21, 2019
    Date of Patent: March 31, 2020
    Assignees: Rutgers, The State University of New Jersey, The Research Foundation for the State University of New York
    Inventors: David J. Augeri, Anthony F. Bencivenga, Adam Blanden, Darren R. Carpizo, John A. Gilleran, Spencer David Kimball, Stewart N. Loh, Xin Yu
  • Patent number: 10604480
    Abstract: The invention provides compounds of formula I and II and salts thereof, wherein R1, R2, Y, R3, and R4 have any of the meanings described in the specification, as well as compositions comprising such compounds and salts, and methods for treating cancer using such compounds and salts.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: March 31, 2020
    Assignees: Rutgers, The State University of New Jersey, The Research Foundation for the State University of New York
    Inventors: David J. Augeri, Anthony F. Bencivenga, Adam Blanden, Darren R. Carpizo, John A. Gilleran, Spencer David Kimball, Stewart N. Loh, Xin Yu
  • Patent number: 10525021
    Abstract: 2-hydroxy-benzoic anilide compounds and derivatives, compositions thereof, and methods for treating metabolic diseases and cancer through uncoupling mitochondria.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: January 7, 2020
    Assignee: Rutgers, the State University of New Jersey
    Inventors: Shengkan Jin, David J. Augeri, S. David Kimball, Peng Liu, Hanlin Tao, Xiangang Zeng
  • Publication number: 20190256460
    Abstract: The invention provides organic complexes of Zn2+ that are useful for treating cancer, as well as compositions and kits comprising such complexes, and intermediate monomer compounds that are useful for the preparation of such complexes.
    Type: Application
    Filed: January 21, 2019
    Publication date: August 22, 2019
    Applicants: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: David J. Augeri, Anthony F. Bencivenga, Adam Blanden, Darren R. Carpizo, John A. Gilleran, Spencer David Kimball, Stewart N. Loh, Xin Yu
  • Patent number: 10227315
    Abstract: The present disclosure relates to benzamide compounds, prodrugs of the compounds, pharmaceutical compositions containing the compounds and/or the prodrugs and methods of using the compounds, prodrugs and pharmaceutical compositions in the treatment of diseases related to lipid metabolism including diabetes, Non-Alcholic Fatty Liver Disease (NAFLD), Non-Alcholic Steathohepatitis (NASH), diseases caused by abnormal cell proliferation including cancer, psoriasis, and infectious diseases.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: March 12, 2019
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Shengkan Jin, David J. Augeri, Bin Cao, Hanlin Tao
  • Patent number: 10221133
    Abstract: The invention provides organic complexes of Zn2+ of formula (I) that are useful for treating cancer, as well as compositions and kits comprising such complexes, and intermediate monomer compounds that are useful for the preparation of such complexes.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: March 5, 2019
    Assignees: Rutgers, The State University of New Jersey, The Research Foundation for the State University of New York
    Inventors: David J. Augeri, Anthony F. Bencivenga, Adam Blanden, Darren R. Carpizo, John A. Gilleran, Spencer David Kimball, Stewart N. Loh, Xin Yu
  • Publication number: 20180000772
    Abstract: The invention provides complexes of Zn2+ of formulae (la) and (IIa) that are useful for treating cancer, as well as compositions and kits comprising such complexes.
    Type: Application
    Filed: January 27, 2016
    Publication date: January 4, 2018
    Applicants: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY O F NEW YORK
    Inventors: David J. Augeri, Anthony F. Bencivenga, Adam Blanden, Darren R. Carpizo, John A. Gilleran, Spencer David Kimball, Stewart N. Loh, Xin Yu
  • Publication number: 20180000806
    Abstract: The invention provides compounds of formula (I): and salts thereof wherein ring A, R2, HET, X, n, and R3 have any of the meanings described in the specification, as well as compositions comprising such compounds and salts, and methods for treating cancer using such compounds and salts.
    Type: Application
    Filed: January 27, 2016
    Publication date: January 4, 2018
    Applicants: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: David J. Augeri, Anthony F. Bencivenga, Adam Blanden, Darren R. Carpizo, John A. Gilleran, Spencer David Kimball, Stewart N. Loh, Xin Yu
  • Publication number: 20180002279
    Abstract: The invention provides organic complexes of Zn2+ of formula (I) that are useful for treating cancer, as well as compositions and kits comprising such complexes, and intermediate monomer compounds that are useful for the preparation of such complexes.
    Type: Application
    Filed: January 27, 2016
    Publication date: January 4, 2018
    Applicants: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: David J. Augeri, Anthony F. Bencivenga, Adam Blanden, Darren R. Carpizo, John A. Gilleran, Spencer David Kimball, Stewart N. Loh, Xin Yu
  • Publication number: 20180002280
    Abstract: The invention provides compounds of formula I and II and salts thereof, wherein R1, R2, Y, R3, and R4 have any of the meanings described in the specification, as well as compositions comprising such compounds and salts, and methods for treating cancer using such compounds and salts.
    Type: Application
    Filed: January 27, 2016
    Publication date: January 4, 2018
    Applicants: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: David J. Augeri, Anthony F. Bencivenga, Adam Blanden, Darren R. Carpizo, John A. Gilleran, Spencer David Kimball, Stewart N. Loh, Xin Yu
  • Publication number: 20170334869
    Abstract: The present disclosure relates to benzamide compounds, prodrugs of the compounds, pharmaceutical compositions containing the compounds and/or the prodrugs and methods of using the compounds, prodrugs and pharmaceutical compositions in the treatment of diseases related to lipid metabolism including diabetes, Non-Alcholic Fatty Liver Disease (NAFLD), Non-Alcholic Steathohepatitis (NASH), diseases caused by abnormal cell proliferation including cancer, psoriasis, and infectious diseases.
    Type: Application
    Filed: May 18, 2017
    Publication date: November 23, 2017
    Inventors: Shengkan JIN, David J. AUGERI, Bin CAO, Hanlin TAO
  • Publication number: 20170319516
    Abstract: 2-hydroxy-benzoic anilide compounds and derivatives, compositions thereof, and methods for treating metabolic diseases and cancer through uncoupling mitochondria.
    Type: Application
    Filed: November 18, 2015
    Publication date: November 9, 2017
    Inventors: Shengkan JIN, David J. AUGERI, David S. KIMBALL, Peng LIU, Hanlin TAO, Xiangang ZENG
  • Patent number: 8404732
    Abstract: Methods of treating and managing ulcerative colitis, using imidazole-based compounds that inhibit S1P lyase, are disclosed.
    Type: Grant
    Filed: January 4, 2012
    Date of Patent: March 26, 2013
    Assignee: Lexicon Pharmaceuticals, Inc.
    Inventors: David J. Augeri, Jeffrey Bagdanoff, Lakmal W. Boteju, Kenneth G. Carson, Theodore C. Jessop, Spencer David Kimball
  • Publication number: 20130012723
    Abstract: Methods and compounds for production of cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV are provided.
    Type: Application
    Filed: August 31, 2012
    Publication date: January 10, 2013
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Truc Chi Vu, David B. Brzozowski, Rita Fox, Jollie Duaine Godfrey, JR., Ronald L. Hanson, Sergei V. Kolotuchin, John A. Mazzullo, Ramesh N. Patel, Jianji Wang, Kwok Wong, Jurong Yu, Jason J. Zhu, David R. Magnin, David J. Augeri, Lawrence G. Hamann
  • Patent number: RE44186
    Abstract: Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula where x is 0 or 1 and y is 0 or 1 (provided that x=1 when y=0 and x=0 when y=1); n is 0 or 1; X is H or CN; and wherein R1, R2, R3 and R4 are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor *or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: April 30, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey A. Robl, Richard B. Sulsky, David J. Augeri, David R. Magnin, Lawrence G. Hamann, David A. Betebenner